Joaquín Gavilá Gregori

Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial

Fabrice André, Yeon Hee Park, Sung‐Bae Kim et al. · The Lancet · 2023 · 345 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

A design chart approach for the tuning of parallel and trapezoidal bifilar centrifugal pendulum

Marco Cirelli, Joaquín Gavilá Gregori, Pier Paolo Valentini · Mechanism and Machine Theory · 2019 · 38 citations

Engineering, Design, Mechanical Engineering +8

Defining the optimal sequence for the systemic treatment of metastatic breast cancer

Joan Albanell Mestres, A. B. iMolins, Eva Ciruelos Gil et al. · Clinical & Translational Oncology · 2016 · 25 citations · Full text

Medicine, Oncology, Breast Oncology +15

SEOM clinical guidelines in advanced and recurrent breast cancer (2018)

José Ignacio Chacón, Luis de la Cruz‐Merino, Joaquín Gavilá Gregori et al. · Clinical & Translational Oncology · 2019 · 23 citations · Full text

Medicine, Oncology, Breast Oncology +14

Abstract GS2-01: GS2-01 Trastuzumab deruxtecan vs physician’s choice in patients with HER2+ unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine: primary results of the randomized, phase 3 study DESTINY-Breast02

Ian E. Krop, Yeon H. Park, Sung‐Bae Kim et al. · Cancer Research · 2023 · 23 citations

Medicine, Oncology, Pharmacology +16